TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37573936

Group type: EXPERIMENTAL
Intervention: Fondaparinux (62.1% of patients, mean duration 34.9 ± 15.7 days)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (25.0% of patients, mean duration 26.2 ± 23.2 days)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Any other anticoagulants (6.2%)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: No anticoagulant (6.7%)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 872
Study: 37573968

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2180

Group type: EXPERIMENTAL
Intervention: Physician-guided discontinuation
Number of subjects: 2180

Group type: EXPERIMENTAL
Intervention: Disruption of DAPT
Number of subjects: 2180
Study: 37574002

Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 174

Group type: COMPARATOR
Intervention: ROSC
Number of subjects: 174
Study: 37574027

Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Other measured metabolites (except γ-butyrobetaine and carnitine)
Number of subjects: 1683
Study: 37574132

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-d lead-in, 90 mg)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Alectinib 600 mg twice daily
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both treatments (exploratory analysis)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 248

Group type: COMPARATOR
Intervention: Alectinib
Number of subjects: 248
Study: 37574143

Group type: EXPERIMENTAL
Intervention: Antithrombotic group (41 men)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Antithrombotic-naïve group (75 men)
Number of subjects: 116
Study: 37574209

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Transcriptional DDR markers
Number of subjects: 376
Study: 37574463

Group type: EXPERIMENTAL
Intervention: Bipolar-I
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Bipolar-II
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: MDD
Number of subjects: 362

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 362
Study: 37574511

Group type: EXPERIMENTAL
Intervention: Envonalkib
Number of subjects: 264

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 264
Study: 37574558

Group type: EXPERIMENTAL
Intervention: Rotational use of NIV masks every 6 hours.
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard of care NIV mask selection and change based on discomfort or new pressure sores.
Number of subjects: 239
Study: 37574601

Group type: EXPERIMENTAL
Intervention: Exposure to childhood PTEs, particularly direct interpersonal violence
Number of subjects: 2947

Group type: COMPARATOR
Intervention: Psychological symptoms and pain
Number of subjects: 2947
Study: 37574610

Group type: EXPERIMENTAL
Intervention: LEM5 (5 mg)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: LEM10 (10 mg)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo non-responders
Number of subjects: 321
Study: 37574661

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 22
Study: 37574780

Group type: EXPERIMENTAL
Intervention: Ad-HSV1-TK/GCV and Ad-Flt3L gene therapy
Number of subjects: 0
Study: 37574821

Group type: EXPERIMENTAL
Intervention: Tandem infusions of MIITOP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tandem infusions of MIITOP followed by busulfan-melphalan
Number of subjects: 30
Study: 37574953

Group type: EXPERIMENTAL
Intervention: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks (with possible reduction to 300 mg every 4 weeks during the second 26-week period if well-controlled)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lanadelumab
Number of subjects: 12
Study: 37574994

Group type: EXPERIMENTAL
Intervention: Family Partner intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ordinary child welfare services
Number of subjects: 3
Study: 37575149

Group type: EXPERIMENTAL
Intervention: Emollient+ used at least once daily
Number of subjects: 56
Study: 37575193

Group type: EXPERIMENTAL
Intervention: Post-surgical methemoglobin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative hemoglobin concentration (Hb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, myocardial infarction, stroke, severe acute kidney injury at 28 days)
Number of subjects: 0
Study: 37575226

Group type: EXPERIMENTAL
Intervention: Supplementation with live bacteria (specific details not provided in the abstract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided in the abstract)
Number of subjects: 0
Study: 37575326

Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet
Number of subjects: 6
Study: 37575420

Group type: EXPERIMENTAL
Intervention: VR-guided meditation intervention (8 sessions of 15-min each, twice weekly for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VR-guided meditation intervention
Number of subjects: 30
Study: 37575994

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 239

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 239
Study: 37576009

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 44
Study: 37576010

Group type: EXPERIMENTAL
Intervention: Automated lesion segmentation algorithm using a fixed ADC threshold (≤620 × 10-6 mm)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: ADC threshold-based automated delineation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: ADC threshold-based automated delineation of very small lesions
Number of subjects: 108
Study: 37576823

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 37576973

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle-enriched preparations from participants with T1D
Number of subjects: 17

Group type: COMPARATOR
Intervention: Extracellular vesicle-enriched preparations from healthy normal volunteers (Controls)
Number of subjects: 17
Study: 37577112

Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg IM injection
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Sotrovimab 250 mg IM injection
Number of subjects: 1147
Study: 37577293

Group type: EXPERIMENTAL
Intervention: Maintenance intraoperative hypotension (mIOH)
Number of subjects: 4776

Group type: EXPERIMENTAL
Intervention: Post-induction hypotension (pIOH)
Number of subjects: 4776

Group type: EXPERIMENTAL
Intervention: Ephedrine usage, hypothermia, need for additional analgesics, nausea, and vomiting
Number of subjects: 4776

Group type: EXPERIMENTAL
Intervention: Older patients (≥65), patients with ASA≥2 status, those undergoing major surgery, experiencing unexpected bleeding, and exhibiting hypothermia at the end of anesthesia
Number of subjects: 4776
Study: 37577514

Group type: EXPERIMENTAL
Intervention: Multi-level program for reducing cardiometabolic disease risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured lifestyle change education program
Number of subjects: 0
Study: 37577753

Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec gene therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control cohort (external)
Number of subjects: 4
Study: 37577796

Group type: EXPERIMENTAL
Intervention: NCTF®135HA injections plus twice-daily anti-aging moisturizer cream
Number of subjects: 146

Group type: COMPARATOR
Intervention: Anti-aging moisturizer cream alone
Number of subjects: 146
Study: 37577798

Group type: EXPERIMENTAL
Intervention: Mepolizumab (anti-IL-5 therapy)
Number of subjects: 0
Study: 37577801

Group type: EXPERIMENTAL
Intervention: Active treatment (1 Hz rTMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both active and sham groups
Number of subjects: 60
Study: 37577817

Group type: EXPERIMENTAL
Intervention: PegIFNα-2b treatment for 68 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: PegIFNα-2b-based immunotherapy (two cycles with GM-CSF and vaccine treatment)
Number of subjects: 40
Study: 37577933

Group type: EXPERIMENTAL
Intervention: Baseline KVSI (Kidney Venous Stasis Index)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Baseline IKVF pattern (Intrakidney Venous Flow pattern)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Change in KVSI from Doppler 1 to Doppler 2
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Change in IKVF pattern severity from Doppler 1 to Doppler 2
Number of subjects: 216
Study: 37577967

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37578052

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule test
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Questionnaires covering symptom severity and GI-specific quality of life
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Quality of life assessments
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Colon transit time measurement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Assessment of GI symptoms
Number of subjects: 48
Study: 37578099

Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 48 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 144 weeks (exploratory analysis)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Burosumab treatment for 144 weeks (SF-36 v2 scores)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Qualitative data from exit interviews with 8 participants
Number of subjects: 14
Study: 37578100

Group type: EXPERIMENTAL
Intervention: 12-week web-based aerobic exercise programme
Number of subjects: 29
Study: 37578113

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for a duration of 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis for a duration longer than 24 hours
Number of subjects: 0
Study: 37578188

Group type: EXPERIMENTAL
Intervention: Glucose-lowering therapies
Number of subjects: 40339
Study: 37578437

Group type: EXPERIMENTAL
Intervention: Cooled Lumbar Radiofrequency Ablation (C-LRFA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Facet Joint Injection (FIJ)
Number of subjects: 32
Study: 37578485

Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain frequency
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain intensity
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vaso-occlusive crisis pain duration
Number of subjects: 198
Study: 37578567

Group type: EXPERIMENTAL
Intervention: Preoperative MRCP
Number of subjects: 180

Group type: COMPARATOR
Intervention: Complementary perioperative imaging
Number of subjects: 180
Study: 37578791

Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM) administered once daily via intravenous infusion for 14 days.
Number of subjects: 3448

Group type: COMPARATOR
Intervention: Placebo administered once daily via intravenous infusion for 14 days.
Number of subjects: 3448

Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM) and placebo (both groups).
Number of subjects: 3448
Study: 37578800

Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 630

Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa
Number of subjects: 630
Study: 37578804

Group type: EXPERIMENTAL
Intervention: Hybrid Closed-Loop System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37578827

Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training (EMI) combined with EMA
Number of subjects: 93

Group type: COMPARATOR
Intervention: EMA only (Control group)
Number of subjects: 93
Study: 37579053

Group type: EXPERIMENTAL
Intervention: Leflutrozole 0.1 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Leflutrozole 0.3 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Leflutrozole 1.0 mg
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Leflutrozole (all doses)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Leflutrozole (0.1 mg, 0.3 mg, 1.0 mg)
Number of subjects: 271
Study: 37579108

Group type: EXPERIMENTAL
Intervention: NicoBloc
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 45
Study: 37579116

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg subcutaneously once-weekly for 6 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard individual drug counseling
Number of subjects: 3
Study: 37579130

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37579214

Group type: EXPERIMENTAL
Intervention: rhIGF-1 (mecasermin, Increlex)
Number of subjects: 306
Study: 37579253

Group type: EXPERIMENTAL
Intervention: Genetic testing for germline mutations in lung cancer patients
Number of subjects: 141
Study: 37579304

Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training intervention
Number of subjects: 25
Study: 37579572

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) intervention for 26 months
Number of subjects: 200
Study: 37579773

Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (0.5 mL, months 0 and 6)
Number of subjects: 1610

Group type: COMPARATOR
Intervention: MenB-FHbp and MenACWY-CRM (two doses of MenB-FHbp and one dose of MenACWY-CRM)
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Number of subjects: 1610

Group type: COMPARATOR
Intervention: MenB-FHbp
Number of subjects: 1610

Group type: COMPARATOR
Intervention: MenB-FHbp and MenACWY-CRM
Number of subjects: 1610
Study: 37579884

Group type: EXPERIMENTAL
Intervention: ABM
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 301
Study: 37579943

Group type: EXPERIMENTAL
Intervention: Primary out-of-hospital CS admitted during off-hours
Number of subjects: 273

Group type: COMPARATOR
Intervention: Secondary in-hospital CS
Number of subjects: 273

Group type: COMPARATOR
Intervention: AMI related secondary in-hospital CS
Number of subjects: 273
Study: 37580026

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine/Chloroquine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 37580032

Group type: EXPERIMENTAL
Intervention: Homestead food production intervention (home gardening and poultry rearing, child nutrition and health counseling)
Number of subjects: 3276

Group type: EXPERIMENTAL
Intervention: Homestead food production intervention
Number of subjects: 3276
Study: 37580090

Group type: EXPERIMENTAL
Intervention: Online evidence-based leadership training
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional online training (reading material only)
Number of subjects: 300
Study: 37580112

Group type: EXPERIMENTAL
Intervention: PIK3CA-related overgrowth spectrum (PROS) patients
Number of subjects: 267

Group type: COMPARATOR
Intervention: Wilms tumor/nephrogenic rests
Number of subjects: 267

Group type: COMPARATOR
Intervention: Other cancers
Number of subjects: 267
Study: 37580231

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 37580232

Group type: EXPERIMENTAL
Intervention: Potato consumption <1/week
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Potato consumption 1/week
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Potato consumption 2-4/week
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Potato consumption 5+/week
Number of subjects: 2208
Study: 37580338

Group type: EXPERIMENTAL
Intervention: Edoxaban uninterrupted during cleaning procedures (53/68, 77.9%)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Edoxaban interrupted for single tooth extractions (67/100, 67.0%)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Edoxaban interrupted for multiple tooth extractions (16/30, 53.3%)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Noncleaning procedures with uninterrupted edoxaban (not specified)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Overall management of edoxaban during dental procedures
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Overall bleeding rates during procedures
Number of subjects: 196
Study: 37580352

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib (cohort 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib (cohort 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 72
Study: 37580498

Group type: EXPERIMENTAL
Intervention: MP-AzeFlu nasal spray (one spray per nostril twice daily for 14 days)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray (AZE)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FLU)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: MP-AzeFlu nasal spray
Number of subjects: 900
Study: 37580534

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation to the cerebellar dentate nucleus combined with renewed physical rehabilitation
Number of subjects: 12
Study: 37580610

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 53
Study: 37580653

Group type: EXPERIMENTAL
Intervention: Financial education paired with housing support and trauma-informed counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policy changes to address structural racism
Number of subjects: 0
Study: 37580657

Group type: EXPERIMENTAL
Intervention: HBV genotyping
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: HDV genotyping
Number of subjects: 834
Study: 37580658

Group type: EXPERIMENTAL
Intervention: Positive Emotions Training (PoET)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 101
Study: 37580661

Group type: EXPERIMENTAL
Intervention: Anlotinib 8 mg once daily and Fluzoparib 150 mg twice daily until disease progression or intolerable toxicity
Number of subjects: 50
Study: 37580663

Group type: EXPERIMENTAL
Intervention: Loading dose of enteral cholecalciferol (10,000 IU/kg, maximum of 400,000 IU)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 37580666

Group type: EXPERIMENTAL
Intervention: Targeted animation video for men aged 16-24 years
Number of subjects: 186113

Group type: EXPERIMENTAL
Intervention: General animation video
Number of subjects: 186113

Group type: COMPARATOR
Intervention: No video (control group)
Number of subjects: 186113
Study: 37580739

Group type: EXPERIMENTAL
Intervention: Distorted Thoughts Scale (DTS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cognitive distortions as a mediator
Number of subjects: 119
Study: 37580773

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET) including letrozole, fulvestrant, or tamoxifen with goserelin.
Number of subjects: 87
Study: 37580777

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 76
Study: 37580782

Group type: EXPERIMENTAL
Intervention: Prophylactic placement of ProGrip™ mesh in an onlay position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized abdominal closure without mesh
Number of subjects: 0
Study: 37580788

Group type: EXPERIMENTAL
Intervention: 12-week gamified family-based health and exercise intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study: 37580795

Group type: EXPERIMENTAL
Intervention: Implementation strategies for PrEP delivery in MCH clinics
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Stakeholder engagement and prioritization of strategies
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Barriers to PrEP delivery
Number of subjects: 146
Study: 37580800

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (IMT + NMES + pulmonary rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT + pulmonary rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES + pulmonary rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation
Number of subjects: 40
Study: 37580810

Group type: EXPERIMENTAL
Intervention: FBT-HT
Number of subjects: 90

Group type: COMPARATOR
Intervention: FBT
Number of subjects: 90

Group type: COMPARATOR
Intervention: FBT-MBSR
Number of subjects: 90
Study: 37580815

Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with individual-level clinician data, data relevant to MBC barriers, and information requested by data recipients.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with aggregate data summaries.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) with data accuracy concerns addressed.
Number of subjects: 6
Study: 37580831

Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet (mediSCORE ≥ 6)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Low adherence to the Mediterranean diet
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: High GRS with adherence to the Mediterranean diet
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Low GRS with adherence to the Mediterranean diet
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Interaction of GRS and adherence to the Mediterranean diet
Number of subjects: 612
Study: 37580836

Group type: EXPERIMENTAL
Intervention: HCW-delivered Adolescent Transition Package (ATP) via phone delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptations made to the ATP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context adaptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Content adaptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation process adaptations
Number of subjects: 0
Study: 37580838

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: N-DEX (no dexmedetomidine)
Number of subjects: 45